Medpace officer Form 4 shows 20,000-share insider sale, 27,500 left

Rhea-AI Filing Summary

Medpace Holdings, Inc. executive reports stock sale

A Medpace Holdings, Inc. executive vice president of operations filed a Form 4 reporting the sale of 20,000 shares of Medpace common stock on 11/24/2025. The shares were sold at a weighted average price of $609.15 per share, through multiple trades within a price range of $607.59 to $610.92, executed under a pre-placed limit order during an open trading window. Following this transaction, the reporting person directly holds 27,500 shares of Medpace common stock.

Insider Trade Summary

Net Seller: 20,000 shares ($12,183,000)

Net Sell 1 txn

Insider BURWIG SUSAN E

Role Exec. VP, Operations

Sold 20,000 shs ($12.18M)

Type	Security	Shares	Price	Value
Sale	Common Stock	20,000	$609.15	$12.18M

Holdings After Transaction: Common Stock — 27,500 shares (Direct)

Footnotes (1)

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $607.59 to $610.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		S(1)		20,000	D	$609.15(2)	27,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $607.59 to $610.92. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Medpace Holdings (MEDP) report on this Form 4?

The filing reports that an executive vice president of Medpace Holdings, Inc. sold 20,000 shares of Medpace common stock on 11/24/2025.

At what price were the Medpace (MEDP) shares sold in this insider transaction?

The shares were sold at a weighted average price of $609.15 per share, in multiple trades ranging from $607.59 to $610.92.

How many Medpace (MEDP) shares does the reporting person own after the sale?

After the reported sale, the executive directly owns 27,500 shares of Medpace common stock.

What is the role of the Medpace (MEDP) insider who filed this Form 4?

The reporting person is an officer of Medpace Holdings, Inc., serving as Executive Vice President, Operations.

Was the Medpace (MEDP) insider sale executed under a pre-arranged trading instruction?

Yes. The filing notes the trades were effected under a limit order placed during an open window period by the reporting person.

Does the Form 4 provide details on the individual trade prices for the Medpace (MEDP) sale?

The filing states the price is a weighted average and that individual trade prices ranged from $607.59 to $610.92, with full trade details available on request.